Research Details

Semax Scientific Research Overview Semax is a synthetic peptide derived from the ACTH 4–7 sequence with an added proline-glycine-proline segment. It has been studied in relation to neurotrophic signaling, cerebral ischemia, inflammatory gene expression, oxidative stress, learning, memory, and neurological recovery. Much of the clinical literature originated in Russia and involves relatively small studies compared with modern multinational drug-development programs. Published Research Findings An early clinical study involving 30 patients during the acute period of hemispheric ischemic stroke reported neurological improvement associated with Semax treatment. The small study provided preliminary clinical support but was not sufficient to establish broad treatment efficacy. A later study followed 110 patients after ischemic stroke and reported that Semax administration increased circulating BDNF levels. Higher BDNF levels were associated with faster functional recovery, improvements in Barthel Index measurements, and stronger outcomes when combined with early rehabilitation. Additional clinical and animal research has investigated Semax’s influence on inflammatory signaling and gene-expression pathways following cerebral ischemia. Experimental models have reported reductions in several pro-inflammatory messenger-RNA signals, supporting continued research into potential neuroprotective mechanisms. Evidence and Regulatory Context Semax is not an FDA-approved drug. FDA’s 2026 review identified limitations in the available clinical literature, including small studies, incomplete methodological detail, and limited safety information. FDA also identified potential peptide-quality and immunogenicity concerns and proposed that Semax-related substances not be included on the Section 503A Bulks List. Research Links Semax in Acute Hemispheric Ischemic Stroke Semax, BDNF and Post-Stroke Functional Recovery Clinical Investigation of Semax Neuroprotective Mechanisms Semax and Experimental Inflammatory Gene Expression FDA 2026 PCAC Meeting Materials Research Context: Published findings summarized on this page involve limited clinical studies, preclinical experiments, and study-specific Semax formulations. Much of the clinical evidence comes from small or regionally published studies that have not been confirmed through large modern multicenter trials. These findings do not establish the identity, purity, sterility, safety, effectiveness, or regulatory status of the research material offered on this page. This product is sold strictly for lawful laboratory research and is not intended for human or veterinary use.